Irradiated Blood Usage in a Tertiary-care Hospital

Jeong Hyun Kim; Duck-An Kim

doi:10.3343/kjlm.2006.26.5.369

Journal List > Korean J Lab Med > v.26(5) > 1011345

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim and Kim: Irradiated Blood Usage in a Tertiary-care Hospital

Original Article

Korean J Leg Med 2006;26(5):369-373.

Published online: 10 February 2006

DOI: https://doi.org/10.3343/kjlm.2006.26.5.369

Irradiated Blood Usage in a Tertiary-care Hospital

Jeong Hyun Kim, M.D., Duck-An Kim, M.D.

Department of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea

Received 26 April 2006 Revised 24 July 2006 Accepted 12 August 2006

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Irradiated blood is used to prevent transfusion-associated graft-versus host disease in high risk patients. The guidelines for usage of irradiated blood components vary from one country to other according to their needs. But in Korea, little information is available on the current usage of and the guidelines for irradiated blood. Therefore, we analyzed the usage of irradiated blood components in Hanyang University Medical Center.

Methods

Medical records were reviewed for 187 patients who had been transfused with irradiated blood products during the period from January 2004 to June 2005. And we investigated the proportion of irradiated blood products among the total number of blood products that were transfused during a one-year period.

Results

Hematologic diseases and solid cancer patients comprised 63.7% and 24.6% respectively. The proportion of irradiated blood products among the total blood components were 25.7% of platelet concentrates, 61.4% of apheresis platelets, and 5.1% of packed red cells. Total transfused amount by disease categories and the average transfused units per patient of irradiated blood components were high in a group of patients with several hematologic diseases such as acute leukemia.

Conclusions

The use of irradiated blood components takes a great proportion in total blood product transfusions and the majority of blood components were transfused to a group of patients with a few hematologic diseases. The proper use of blood should be guided by the promotion and education of a modified usage protocol for irradiated blood products and by a continuous data analysis.

Keywords: Blood irradiation, GVHD, transfusion

References

1. Ohto H, Anderson KC. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev. 1996; 10:31–43.

2. Seghatchian MJ, Ala F. Transfusion-associated graft-versus-host disease: current concepts and future trends. Transfus Sci. 1995; 16:99–105.

3. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion. 1995; 35:284–91.

4. Ahya R, Douglas G, Watson HG. Transfusion associated graft versus host disease in an immunocompetent individual following coronary artery bypass grafting. Heart. 1998; 80:299–300.

5. Cassens U, Greve B, Tapernon K, Nave B, Severin E, Sibrowski W, et al. A novel true volumetric method for the determination of residual leucocytes in blood components. Vox Sang. 2002; 82:198–206.

6. Kao KJ, Mickel M, Braine HG, Davis K, Enright H, Gernsheimer T, et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. Transfusion. 1995; 35:13–9.

7. Webb IJ, Anderson KC. Transfusion-associated graft-versus-host disease. Scientific basis of transfusion medicine: Implications for clinical practice. 2nd edition.Anderson KC, Ness PM, ed. Philadelphia: WB Saunders Company;2000. p. 420–6.

8. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Hematol. 2002; 117:275–87.

9. Kim SI, Han KS, Kwon SW. A New, simple method for preparing leukocyte-poor red blood cells employing intestina1 clamp. Korean J Hematol. 1990; 25:181–5.

10. Hayashi H, Nishiuchi T, Tamura H, Takeda K. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology. 1993; 79:1419–21.

11. Przepiorka D, LeParc GF, Stovall MA, Werch J, Lichtiger B. Use of irradiated blood components: practice parameter. Am J Clin Pathol. 1996; 106:6–11.

12. World Health Organization. International Statistical classification of disease and related health problems,. 10th ed.Geneva: World Health Organization;1992.

13. National Statistical Office. Korean standard classification of diseases. 3rd ed.Seoul: Korean Medical Record Association;1994. p. 1–114.

14. Seo DH, Kang JW, Oh YC, Han KS, Kim SI. Utilization of blood components for transfusion by hospitals in Korea(1998–99). Korean J Blood Transfus. 2001; 12:11–8.

15. Lim YA, Hyun BH. Blood Use According to Diagnoses in Hospitalized Adults of Ajou University Hospital. Korean J Clin Pathol. 2001; 21:79–85.

16. Lee SK, Jeon MJ, Shin JH, Suh SP, Ryang DW. Use of blood components, irradiated and filtered blood products in Chonnam niversity hospital. Korean J Blood Transfus. 1997; 8:231–8.

17. McCullough J. The nation's changing blood supply system. JAMA. 1993; 269:2239–45.

18. Blood program in Japan. Blood Product Research Organization. 1995.

19. Cha MS, Lee KH, Min YH, Lee KG. Transfusion-associated graft-versus-host disease in patients with acute leukemia. Korean J Dermatol. 1996; 34:345–9.

20. van der Mast BJ, van den Dorpel MA, Drabbels JJ, Claas FH, Weimar W. Transfusion-associated graft vs. host disease after donor-specific leukocyte transfusion before kidney transplantation. Clin Transplant. 2003; 17:477–83.

21. Aoun E, Shamseddine A, Chehal A, Obeid M, Taher A. Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center. Transfusion. 2003; 43:1672–6.

22. Yasuura K, Okamoto H, Matsuura A. Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg. 2000; 41:377–80.

23. Hume H, Blanchette V, Strauss RG, Levy GJ. A survey of Canadian neonatal blood transfusion practices. Transfus Sci. 1997; 18:71–80.

24. Ohto H, Yasuda H, Noguchi M, Abe R. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion. 1992; 32:691–3.

25. Asai T, Inaba S, Ohto H, Osada K, Suzuki G, Takahashi K, et al. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan. Transfus Med. 2000; 10:315–20.

26. Blood services committee. Guidelines for irradiation of blood and blood components. 2nd ed.New York: New York State council on human blood and transfusion services;2004.

27. Australian and New Zealand society of blood transfusion. Guidelines for gamma irradiation of blood components. 2nd ed.Australia: Australian & New Zealand society of blood transfusion inc.;2003.

Fig. 1.

Percentage of irradiated platelet concentrate usage according to disease categories.

Table 1.

Disease categories of the patients transfused with irradiated blood components

Disease categories	N. of patients (%)
Acute myeloid leukemia	21 (11.2)
Acute lymphocytic leukemia	13 (7.0)
Non-classified leukemia	1 (0.5)
Lymphoma	29 (15.5)
Aplastic anemia	22 (11.8)
Multiple myeloma	11 (5.9)
Idiopathic thrombocytopenic purpura	6 (3.2)
Myelodysplastic syndrome	5 (2.7)
Other hematologic disease	11 (5.9)
Solid cancer	46 (24.6)
Connective tissue disease	6 (3.2)
Others	19 (10.2)
Total patients	187 (100)

Table 2.

Percentage of irradiated blood components to the total blood components for year 2004

	N. of total blood units	N. (%) of irradiated blood units
Platelet concentrates	23,544	6,038 (25.7%)
Platelet pheresis	1,174	721 (61.4%)
Packed red cells	18,980	975 (5.1%)

Table 3.

Total amount of irradiated blood components used according to disease categories and percentage per total irradiated blood use

Disease categories	PC, unit (%)	PP, unit (%)	PRC, unit (%)
Acute myeloid leukemia	2,400 (29.6)	448 (42.1)	430 (28.3)
Acute lymphocytic leukemia	1,762 (21.8)	175 (16.5)	239 (15.8)
Aplastic anemia	1,258 (15.5)	208 (19.6)	238 (15.7)
Myelodysplastic syndrome	300 (3.7)	16 (1.5)	30 (2.0)
Multiple myeloma	340 (4.2)	42 (4.0)	64 (4.2)
Lymphoma	1,045 (12.9)	75 (7.1)	177 (11.7)
Solid cancer	369 (4.6)	13 (1.2)	197 (13.0)
Others	625 (7.7)	86 (8.1)	142 (9.4)
Total	8,099 (100)	1,063 (100)	1,517 (100)

Abbreviations: PC, platelet concentrate; PP, platelet pheresis; PRC, packed red cells.

Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; AA, aplastic anemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; solid ca, solid cancer.

Table 4.

Average units of irradiated blood components transfused per person according to disease categories during an 18-month period

Disease categories	PC	PP	PRC
Acute myeloid leukemia	114.3	21.3	20.5
Acute lymphocytic leukemia	135.5	13.5	18.4
Aplastic anemia	57.2	9.5	10.8
Myelodysplastic syndrome	60	3.2	6.0
Multiple myeloma	30.9	3.8	5.8
Lymphoma	36.0	2.6	6.1
Solid cancer	8.0	0.3	4.3
Other	15.6	2.2	3.6

Abbreviations: See Table 2.

TOOLS

Similar articles